JP2016519654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519654A5 JP2016519654A5 JP2016501507A JP2016501507A JP2016519654A5 JP 2016519654 A5 JP2016519654 A5 JP 2016519654A5 JP 2016501507 A JP2016501507 A JP 2016501507A JP 2016501507 A JP2016501507 A JP 2016501507A JP 2016519654 A5 JP2016519654 A5 JP 2016519654A5
- Authority
- JP
- Japan
- Prior art keywords
- tube
- carrier material
- beneficial agent
- beneficial
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009286 beneficial effect Effects 0.000 claims 16
- 239000012876 carrier material Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 239000011148 porous material Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 3
- 229910052710 silicon Inorganic materials 0.000 claims 3
- 239000010703 silicon Substances 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229910021426 porous silicon Inorganic materials 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 239000012890 simulated body fluid Substances 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778111P | 2013-03-12 | 2013-03-12 | |
| US61/778,111 | 2013-03-12 | ||
| PCT/US2014/024362 WO2014165097A1 (en) | 2013-03-12 | 2014-03-12 | Drug delivery device comprising silicon-based carrier particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519654A JP2016519654A (ja) | 2016-07-07 |
| JP2016519654A5 true JP2016519654A5 (enExample) | 2017-04-13 |
| JP6568513B2 JP6568513B2 (ja) | 2019-08-28 |
Family
ID=51659062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501507A Expired - Fee Related JP6568513B2 (ja) | 2013-03-12 | 2014-03-12 | シリコン系担体粒子を含む薬物送達デバイス |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140309610A1 (enExample) |
| EP (1) | EP2968882B1 (enExample) |
| JP (1) | JP6568513B2 (enExample) |
| CN (1) | CN105025974A (enExample) |
| AU (1) | AU2014248707B2 (enExample) |
| CA (1) | CA2904204A1 (enExample) |
| HK (1) | HK1216864A1 (enExample) |
| RU (1) | RU2695536C2 (enExample) |
| WO (1) | WO2014165097A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016204026A1 (ja) * | 2015-06-15 | 2016-12-22 | ｓｅｖｅｎ ｄｒｅａｍｅｒｓ ｌａｂｏｒａｔｏｒｉｅｓ株式会社 | 鼻腔留置デバイス |
| JP7278223B2 (ja) * | 2017-06-13 | 2023-05-19 | アイポイント ファーマシューティカルズ，インコーポレイティド | 生体浸食性薬物送達デバイス |
| CA3082793C (en) * | 2017-09-13 | 2024-04-16 | Massachusetts Institute Of Technology | Microdevices with complex geometries |
| CN109001188B (zh) * | 2018-08-12 | 2021-09-14 | 河北农业大学 | 一种金刚烷胺和金刚乙胺的特异性分子印迹聚合物、化学发光试剂盒、检测方法及应用 |
| WO2021013861A1 (en) * | 2019-07-22 | 2021-01-28 | Nanomi, B.V. | Sustained release trepostinil-compound microparticle compositions |
| EP4051238A1 (en) * | 2019-11-27 | 2022-09-07 | Oak Crest Institute of Science | Sustained release drug delivery device |
| CN112137984B (zh) * | 2020-10-30 | 2023-02-03 | 四川制药制剂有限公司 | 头孢克洛胶囊及其制备工艺 |
| CN114948864A (zh) | 2021-02-26 | 2022-08-30 | 奈力生医股份有限公司 | 用于将药剂递送到眼后段的方法和其用途 |
| CN118059373A (zh) * | 2022-11-23 | 2024-05-24 | 中国科学院深圳先进技术研究院 | 抑制交感神经的医疗器械及其制备方法 |
| US12390420B1 (en) | 2024-10-22 | 2025-08-19 | Bryet Us, Inc. | Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3214667C2 (de) * | 1982-04-21 | 1985-07-18 | Akzo Gmbh, 5600 Wuppertal | Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen |
| GB9815819D0 (en) * | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
| JP2002533380A (ja) * | 1998-12-23 | 2002-10-08 | アルザ・コーポレーション | 多孔性粒子を含む剤形 |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| GB0104383D0 (en) * | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
| CA2460334A1 (en) * | 2001-09-14 | 2003-03-27 | Francis J. Martin | Microfabricated nanopore device for sustained release of therapeutic agent |
| CA2696139C (en) * | 2007-07-10 | 2018-04-17 | The Regents Of The University Of California | Materials and methods for delivering compositions to selected tissues |
| WO2010111627A1 (en) * | 2009-03-26 | 2010-09-30 | Psivida Us, Inc. | Implantable formulations of bisphosphonic acids |
| CA2785468A1 (en) * | 2009-12-23 | 2011-06-30 | Psivida Us, Inc. | Sustained release delivery devices |
| JP6026424B2 (ja) * | 2010-11-01 | 2016-11-16 | シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． | 治療薬送達のための生物浸食性ケイ素ベースのデバイス |
| US20120238994A1 (en) * | 2010-12-22 | 2012-09-20 | Martin Nazzaro | Two-piece injectable drug delivery device with heat-cured seal |
| EP2673049A4 (en) * | 2011-02-11 | 2015-04-08 | Psivida Inc | METHOD FOR THE TREATMENT OF MOLECULAR SOILS WITH ANTIOTE THERAPEUTICS |
| EP3120834A1 (en) * | 2011-08-29 | 2017-01-25 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
-
2014
- 2014-03-12 JP JP2016501507A patent/JP6568513B2/ja not_active Expired - Fee Related
- 2014-03-12 HK HK16104878.1A patent/HK1216864A1/zh unknown
- 2014-03-12 CN CN201480012001.6A patent/CN105025974A/zh active Pending
- 2014-03-12 CA CA2904204A patent/CA2904204A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/024362 patent/WO2014165097A1/en not_active Ceased
- 2014-03-12 EP EP14779965.4A patent/EP2968882B1/en active Active
- 2014-03-12 US US14/206,823 patent/US20140309610A1/en not_active Abandoned
- 2014-03-12 AU AU2014248707A patent/AU2014248707B2/en active Active
- 2014-03-12 RU RU2015132216A patent/RU2695536C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519654A5 (enExample) | ||
| RU2015132216A (ru) | Устройство для доставки лекарственных средств, содержащее частицы носителя на основе кремния | |
| Jeon et al. | Functional nanoporous membranes for drug delivery | |
| Hoare et al. | A magnetically triggered composite membrane for on-demand drug delivery | |
| Zhou et al. | Thermoresponsive layer-by-layer assemblies for nanoparticle-based drug delivery | |
| JP2010179112A5 (enExample) | ||
| RU2014124120A (ru) | Элютирующие медицинские устройства | |
| US20170151424A1 (en) | Method for Increasing the Permeability of an Epithelial Barrier | |
| JP2015502774A5 (enExample) | ||
| RU2016108968A (ru) | Многоблочные устройства для доставки лекарственного средства и способы доставки лекарственного средства | |
| BR112013002363A2 (pt) | moldes de dispositivo oftálmico formados de copolímero de álcool vinílico solúvel em água, dispositivo oftálmicos moldados nos mesmos, e métodos relacionados | |
| WO2012020332A2 (en) | Injection molded microneedle array and method for forming the microneedle array | |
| JP2011520813A5 (enExample) | ||
| WO2017043517A1 (ja) | マイクロニードルアレイ | |
| JP2018517735A5 (enExample) | ||
| JP2012507721A (ja) | 使い捨てマイクロ流体デバイス用基板 | |
| RU2013135267A (ru) | Медицинский материал и половолоконный мембранный модуль | |
| US20210402355A1 (en) | Nanoparticles for use in membranes | |
| CN203493942U (zh) | 一种复合石墨烯水凝胶药物载体 | |
| Ou et al. | Improvement of the swelling properties of ionic hydrogels by the incorporation of hydrophobic, elastic microfibers for forward osmosis applications | |
| Gu et al. | Response of swelling behavior of weak branched poly (ethylene imine)/poly (acrylic acid) polyelectrolyte multilayers to thermal treatment | |
| JP5754612B2 (ja) | 創傷被覆材 | |
| JP2013163031A5 (enExample) | ||
| JP2014514104A5 (enExample) | ||
| JP2014508933A5 (enExample) |